Etiotropic therapy of the new coronavirus infection. Expectations and realities. Part 2

Abstract

Part 2 of the review includes an analysis of the literature data related to the etiotropic therapy of a new coronavirus infection using drugs from the group of monoclonal antibodies and viral protease inhibitors. The difficulty of choosing a drug for the treatment of a new coronavirus infection caused by the Omicron strain due to the high degree of mutation is emphasized. The mechanism of action of the combined drug Paxlovid, consisting of nirmatrelvir and ritonavir, is described, data on its high efficacy and safety obtained in randomized multicenter placebo-controlled trials are presented. Attention is drawn to the World Health Organization recommendations on the use of this drug in people at high risk of a severe course of a new coronavirus infection and the need for early diagnosis of clinical symptoms for the timely appointment of etiotropic therapy.

 

Keywords

new coronavirus infection / COVID-19 / outpatient practice / etiotropic treatment / monoclonal antibodies / bamlanivimab and etesevimab / casirivimab and imdevimab / sotrovimab / nirmatrelvir and ritonavir / treatment efficacy / side effects

References

[1] Otslezhivanie variantov virusa SARS-CoV-2 [Internet]. WHO. Available from: https://www.who.int/ru/activities/tracking-SARS-CoV-2-variants. Accessed: June 2, 2022. (In Russ.)

[2] Отслеживание вариантов вируса SARS-CoV-2 [Электронный ресурс] // ВОЗ. Режим доступа: https://www.who.int/ru/activities/tracking-SARS-CoV-2-variants. Дата обращения: 02.06.2022.

[3] Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. DOI: 10.1016/j.cell.2021.12.032

[4] Hoffmann M., Krüger N., Schulz S. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic // Cell. 2022. Vol. 185, No. 3. P. 447–456.e11. DOI: 10.1016/j.cell.2021.12.032

[5] Vremennye metodicheskie rekomendatsii. Diagnostika, profilaktika i lechenie novoi koronavirusnoi infektsii (COVID-19), versiya 14 (27.12.2021) [Internet]. Available from: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/1213/attach/vmr_COVID-19_V14_27-12-2021.pdf. Accessed: June 2, 2022

[6] Временные методические рекомендации. Диагностика, профилактика и лечение новой коронавирусной инфекции (COVID-19), версия 14 (27.12.2021) [Электронный ресурс]. Режим доступа: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/1213/attach/vmr_COVID-19_V14_27-12-2021.pdf. Дата обращения: 02.06.2022.

[7] Lekarstvennaya terapiya pri COVID-19. Variativnye rekomendatsii. 24.09.2021 [Internet]. Available from: https://apps.who.int/iris/bitstream/handle/10665/345356/WHO-2019-nCoV-therapeutics-2021.3-rus.pdf. Accessed: June 2, 2022. (In Russ.)

[8] Лекарственная терапия при COVID-19. Вариативные рекомендации. 24.09.2021 [Электронный ресурс]. Режим доступа: https://apps.who.int/iris/bitstream/handle/10665/345356/WHO-2019-nCoV-therapeutics-2021.3-rus.pdf. Дата обращения: 02.06.2022.

[9] Postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 03.04.2020 No. 441 [Internet]. Ofitsial’nyi internet-portal pravovoi informatsii (pravo.gov.ru). Available from: http://publication.pravo.gov.ru/Document/View/0001202004060038. Accessed: June 2, 2022. (In Russ.)

[10] Постановление Правительства Российской Федерации от 03.04.2020 № 441 [Электронный ресурс] // Официальный интернет-портал правовой информации (pravo.gov.ru). Режим доступа: http://publication.pravo.gov.ru/Document/View/0001202004060038. Дата обращения: 02.06.2022.

[11] Heo YA. Sotrovimab: First Approval. Drugs. 2022;82(4):477–484. DOI: 10.1007/s40265-022-01690-7

[12] Heo Y.A. Sotrovimab: First Approval // Drugs. 2022. Vol. 82, No. 4. P. 477–484. DOI: 10.1007/s40265-022-01690-7

[13] Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial. medRxiv. 2021. DOI: 10.1101/2021.11.03.21265533

[14] Gupta A., Gonzalez-Rojas Y., Juarez E. et al. Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial // medRxiv. 2021. DOI: 10.1101/2021.11.03.21265533

[15] Spravochnik lekarstvennykh sredstv VIDAL [Internet]. Available from: https://www.vidal.ru/novosti/preparat-sotrovimab-dlya-lecheniya-covid-19-legkoj-i-srednej-stepeni-tyazhesti-u-patsientov-10462. Accessed: June 2, 2022. (In Russ.)

[16] Справочник лекарственных средств VIDAL [Электронный ресурс]. Режим доступа: https://www.vidal.ru/novosti/preparat-sotrovimab-dlya-lecheniya-covid-19-legkoj-i-srednej-stepeni-tyazhesti-u-patsientov-10462. Дата обращения: 02.06.2022.

[17] Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.

[18] Aleem A., Akbar Samad A.B., Slenker A.K. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). 2022 May 12. // StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.

[19] COVID-19 Treatment Guidelines [Internet]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/?utm_source=site&utm_medium=home&utm_campaign=highlights. Accessed: June 2, 2022.

[20] COVID-19 Treatment Guidelines [Электронный ресурс]. Режим доступа: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/?utm_source=site&utm_medium=home&utm_campaign=highlights. Дата обращения: 02.06.2022.

[21] Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. DOI: 10.1136/bmj.n2713

[22] Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports // BMJ. 2021. Vol. 375. P. n2713. DOI: 10.1136/bmj.n2713

[23] Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. DOI: 10.1056/NEJMoa2118542

[24] Hammond J., Leister-Tebbe H., Gardner A. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 // N. Engl. J. Med. 2022. Vol. 386, No. 15. P. 1397–1408. DOI: 10.1056/NEJMoa2118542

[25] VOZ rekomenduet k primeneniyu effektivnoe lekarstvo ot COVID-19 [Internet]. WHO. Available from: https://news.un.org/ru/story/2022/04/1422402. Accessed: June 2, 2022. (In Russ.)

[26] ВОЗ рекомендует к применению эффективное лекарство от COVID-19 [Электронный ресурс]. Режим доступа: https://news.un.org/ru/story/2022/04/1422402. Дата обращения: 02.06.2022.

[27] Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022. Vol. 386, No. 4. 305–315. DOI: 10.1056/NEJMoa2116846

[28] Gottlieb R.L., Vaca C.E., Paredes R. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients // N. Engl. J. Med. 2022. Vol. 386, No. 4. P. 305–315. DOI: 10.1056/NEJMoa2116846

[29] WHO recommends against the use of remdesivir in COVID-19 patients [Internet]. Available from: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients. Accessed: June 2, 2022.

[30] WHO recommends against the use of remdesivir in COVID-19 patients [Электронный ресурс]. Режим доступа: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients. Дата обращения: 02.06.2022.

RIGHTS & PERMISSIONS

Kuznetsova O.Y.